Quantcast

Pharma news

Aradigm Receives Feedback Following an Oral Explanation With the European Medicines Agency

NEWARK, Calif.–(BUSINESS WIRE)–Aradigm Corporation (OTCQB: ARDM) (“Aradigm” or the “Company”) today announced that following a recent Oral Explanation, it has

Posted in news | Leave a comment

Growth of Age-Related Macular Degeneration (AMD) Therapeutics Market to be Impacted by the Development of Gene Therapy for AMD | Technavio

The market will accelerate at a CAGR of over 8% between 2019-2023 LONDON–(BUSINESS WIRE)–#Biotechnology–The report, global age-related macular degeneration (AMD)

Posted in news | Leave a comment

Exicure to Present at 2019 BIO Investor Forum

CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid

Posted in news | Leave a comment

Charles River Laboratories Schedules Third-Quarter 2019 Earnings Release and Conference Call

  WILMINGTON, Mass.–(BUSINESS WIRE)–$CRL #earnings–Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2019 financial results on Wednesday, November

Posted in news | Leave a comment

Vertex to Announce Third-Quarter 2019 Financial Results on October 30

BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2019 financial results on Wednesday, October 30, 2019 after

Posted in news | Leave a comment

Enanta Pharmaceuticals to Present at the 2019 Wolfe Research Healthcare Conference

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral

Posted in news | Leave a comment

Seattle Genetics’s trial of tucatinib in HER2-positive breast cancer meets primary and secondary endpoints

Seattle Genetics’s trial of tucatinib in HER2-positive breast cancer has met primary and secondary endpoints, showing that the addition of tucatinib was superior to trastuzumab and capecitabine alone, and the company is planning NDA Submission to U.S. FDA for first quarter of 2020.

Posted in news, North America | Tagged , , | Leave a comment

FDA Approves TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation

– For the first time, approximately 6,000 patients with one minimal function mutation and one F508del mutation have a medicine

Posted in news | Leave a comment

Teva Settles Track 1 Opioid Cases and Reaches Agreement on Framework to Settle Remaining Litigation

PARSIPPANY, N.J. & JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. and its affiliates today announced a settlement agreement with both Cuyahoga and

Posted in news, North America | Tagged | Leave a comment

Spanish Government Approves National Reimbursement of Orkambi and Symekevi in Combination With Kalydeco

LONDON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the Spanish Government has approved terms for the national reimbursement of

Posted in Europe, news | Tagged , , | Leave a comment

Eisai, Biogen kick-off phase 3 testing early Alzheimer’s disease antibody, amid dropping aducanunab trial. Eisai’s US company presents AD pipeline

Eisai Co said Friday thata global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer’s disease has been initiated.

Posted in Approval, Asia, Europe, North America, Regions | Tagged , , | Leave a comment

ProMIS offeri potential significant advantage over aducanumab, learns from mistakes

ProMIS Neurosciencesissued a pres release Friday, raising urgency to selectively target the toxic oligomer with exacting precision as part of the global effort to develop disease-modifying therapies for Alzheimer’s disease (AD), upon Biogen’s and Eisai’s dropping two alte-stage clinical trials of aducanumab.

Posted in Approval, North America | Tagged , , , , | Leave a comment

Alvogen’s Taiwan company – Lotus – exchange stake with Fuji Pharma

@alvogenpr subsidiary in Taiwan, Lotus Pharmaceuticals today announced capital and business collaboration agreements with Fuji Pharma in Japan, as Fuji has acquired a 2.0% stake in Lotus for approximately US$20 million (or NT$ 617 million, JPY 2.2 billion). Lotus has also acquired 3.9% stake in Fuji for an equal sum.

Posted in Approval, Asia, Europe, news | Tagged , , | Leave a comment

Gelesis Announces Three Presentations at Annual Endocrine Society Meeting

BOSTON–(BUSINESS WIRE)–Gelesis, a biotechnology company developing first-in-class mechanotherapeutics to treat obesity and other chronic diseases related to the gastrointestinal (GI)

Posted in Approval, news, North America | Tagged | Leave a comment

CB Therapeutics Secures new Research and Production Facility

SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics is an innovative biotechnology company focusing on research and production of cannabinoids. The company utilizes its

Posted in Approval, news | Tagged | Leave a comment

Vaxart Announces Closing of Registered Direct Offering of Common Stock

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather

Posted in Approval, news, North America | Tagged | Leave a comment

First Cancer Patient Receives Dose of Super-Enhancer Inhibitor GZ17-6.02, an Advanced Cancer Drug from Genzada Pharmaceuticals, at HonorHealth Research Institute

STERLING, Kan.–(BUSINESS WIRE)–Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Life Sciences Limited, announced today that the first patient

Posted in Approval, news, North America, Regions | Tagged , , , , | Leave a comment

Transgene: A Positive 2018, Moving Ahead with a Strong Portfolio

2018 Full-year results and business update Clinical trials set to announce key data in 2019 Invir.IO™ platform designed to deliver

Posted in Approval, news | Tagged | Leave a comment

Center for Gene and Cell Therapy Co-founded by Miltenyi and ATLATL in Shanghai

SHANGHAI–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Shanghai?src=hash" target="_blank"gt;#Shanghailt;/agt;–To accelerate the development of cell and gene therapy, ATLATL Center and Miltenyi Biotec have cooperated to build ATLATL-MACS Center

Posted in Approval, Asia, news, Regions | Tagged | Leave a comment

MichBio Announces 7th Annual “Michigan Biosciences Day at the Capitol,” Seeks Participants

ANN ARBOR, Mich. & LANSING, Mich.–(BUSINESS WIRE)–Michigan’s premier biosciences industry trade organization, MichBio, presents its annual Michigan Biosciences Day at

Posted in Approval, news | Tagged | Leave a comment